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The Effectiveness and Value of Treatments for Spinal Muscular Atrophy:  
^ƵŵŵĂƌǇĨƌŽŵƚŚĞ/ŶƐƚŝƚƵƚĞĨŽƌůŝŶŝĐĂůĂŶĚĐŽŶŽŵŝĐZĞǀŝĞǁ ?Ɛ 
New England Comparative Effectiveness Public Advisory Council 
Authors: Steven D. Pearson, MD, MSc; Praveen Thokala, PhD, MASc; Matt Stevenson, PhD, BSc; and 
David Rind, MD, MSc. 
Introduction 
There are two FDA-approved treatments for spinal muscular atrophy (SMA), a rare genetic 
neuromuscular disease affecting approximately one in 10,000 live birth in the United States. 
Spinraza® (nusinersen, Biogen Idec), an antisense oligonucleotide, was approved in 2016 for the 
treatment of any subtype of SMA and targets SMN2 to create more functional SMN protein. It is 
administered via intrathecal injection, with four loading doses (day 0, day 14, day 28, and day 63) 
and maintenance doses every four months thereafter. Zolgensma® (onasemnogene abeparvovec, 
Novartis AG/AveXis), was approved on May 24, 2019 to treat patients less than two years of age 
with any subtype of SMA.  Zolgensma is a gene therapy administered in a single intravenous dose 
that uses the adeno-associated virus serotype 9 vector (AAV9) to deliver a copy of the SMN1 gene 
to replace the native defective or absent gene. 
In this article, we present a summary of the systematic literature review and cost-effectiveness 
analysis of Sprinraza and Zolgensma performed by our research staff at the Institute for Clinical and 
Economic Review (ICER).  We also present the highlights of the deliberation on this evidence review 
and a subsequent policy discussion.  This article includes information contained in an update to the 
ICER report posted on May 24, 2019 that included a synopsis of new evidence that had emerged 
after the ICER meeting and immediately prior to the FDA approval of Zolgensma.  The full updated 
report is available on the ICER website at https://icer-review.org/material/sma-final-evidence-
report/. 
Summary of findings 
Clinical effectiveness  
 
Spinraza: SMA Type I 
 
For a treatment targeting a serious ultra-rare condition, there is a relatively robust evidence base 
on Spinraza.  Overall, we identified four clinical trials, including two RCTs (ENDEAR and 
EMBRACE),1,2  one open-label dose-escalation study (CS3A),3 and one open-label extension 
(SHINE).4  We also included three open-label extended access program (EAP) studies.5-7     
 
For Type I SMA, results were available from both RCTs and the dose-escalation study.  Longer-term 
results were also available for infants in ENDEAR who enrolled in the open-label extension study.8  
In all studies Spinraza demonstrated statistically-significant reductions in the need for ventilatory 
support and improvements in survival.  For example, in the ENDEAR study Spinraza demonstrated a 
47% decrease in the risk of death or permanent assisted ventilation (HR [95% CI]: 0.53 [0.32, 0.89], 
p=0.005).1  Spinraza was also superior to standard of care in improving motor function and 
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milestone achievement.  Although Spinraza is not a cure, among infants with at least six months of 
follow-up in ENDEAR, no infant who received sham achieved any motor milestone, whereas 22% of 
patients who received Spinraza achieved head control and 1% achieved standing with assistance. 
Long-term follow-up data show additional motor milestone achievements for infants receiving 
Spinraza who transitioned from ENDEAR to the open-label extension study. In data from an interim 
analysis (June 15, 2017), after 576 days, approximately 45% of infants achieved full head control 
and 29% were able to sit independently.8 
Spinraza: SMA Types II and III 
For later-onset SMA there was one RCT (CHERISH) of Spinraza versus sham control in children ages 
two to 12 years, and one Phase Ib/IIa open-label study (CS2/CS12) in children ages two through 
15.
9,10 In addition, the sham-controlled EMBRACE trial, which included children with Type I, II, or III, 
presented results on a subgroup of children diagnosed with later-onset SMA.11  
In CHERISH Spinraza demonstrated statistically significant improvements in changes from baseline 
motor function versus the sham control, but new achievements in walking with assistance, standing 
alone, and any motor milestone were similar between Spinraza and sham control groups. There 
were no deaths during CHERISH or CS2/CS12, and no data on permanent ventilation were available.   
Spinraza:  Presymptomatic SMA 
One ongoing, single-arm study (NURTURE) reported on Spinraza treatment in 25 presymptomatic 
infants with two or three copies of SMN2.12,13  As of May 2018, all 25 children were alive and none 
required permanent ventilatory support.  However, many children with one year of follow-up had 
developed one or more clinical symptoms of SMA.  Four (16%) children met the primary outcome of 
requiring non-permanent respiratory intervention (six or more hours per day for seven consecutive 
days, or tracheostomy). All of these children received respiratory intervention during an acute, 
reversible illness, and none required tracheostomy.  With a median time on treatment of 27.1 
months, the mean motor function scores reflected near-maximal function.  Caregivers reported all 
25 children had achieved sitting without support, 22/25 (88%) of children had achieved walking 
with assistance, and 17/25 (68%) had achieved walking alone. 
 
Zolgensma: SMA Type I 
At the time of the original ICER report data were available only from a single small (12 patients) 
open-label, two-cohort clinical trial (CL-101) of Zolgensma and its extension study (START) in Type I 
SMA.14    All infants treated with Zolgensma in CL-101 were alive and event-free through 24 months 
of follow-up.  Improvements in motor function scores were observed among treated infants, with 
92% of patients achieving head control and 17% able to walk independently.  Two more children 
achieved standing with support during additional follow-up in START.15 
In the update to the ICER report we included additional data from ongoing trials of Zolgensma that 
were presented at conferences in April and May 2019.16-18  In a Phase III, single-arm trial (STR1VE) of 
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infants with Type I SMA, 21 of 22 infants treated with Zolgensma were alive with a median age of 
14.4 months.  The single death was deemed not related to treatment. Five months after treatment, 
motor function scores increased by an average of 14.3 points, which was similar to the results from 
the earlier START trial. 
Zolgensma: SMA Type II-III 
As noted earlier, at the time of the original ICER report there were no data reported from trials of 
Zolgensma in presymptomatic SMA or in SMA Types II and III.  Early interim data presented in April 
and May 2019 included results from a phase I dose comparison trial (STRONG) of Zolgensma in 
patients with Type II SMA.  Early results from this trial showed that the treatment was well-
tolerated and a number of the patients achieved new motor milestones.18  
Zolgensma: Presymptomatic SMA 
In the update to the ICER report we summarized conference data from a Phase III single-arm trial 
(SPR1NT) that evaluated Zolgensma in presymptomatic patients with two or three copies of 
SMN2.16  Patients had been diagnosed near the time of birth and were six weeks of age or younger 
at the time of treatment. After a median follow-up of 5.4 months (median age 6.1 months), all 18 
children ǁĞƌĞĂůŝǀĞĂŶĚ “ĞǀĞŶƚĨƌĞĞ ? ?ŵŽŶŐ ?ƉĂƚŝĞŶƚƐǁŝƚŚƚǁŽĐŽƉŝĞƐŽĨ^DE ? (presumed Type I 
SMA), all reportedly achieved age-appropriate motor milestones including 4 who could sit without 
support and one who could stand with assistance.  
Limitations of the evidence 
All trials available at the time of this review showed prolonged survival and improved motor 
function compared with historical controls or sham injections for both Spinraza (SMA Types I-III) 
and Zolgensma (SMA Type I).  However, even after the update to the original ICER report, there 
remain several important uncertainties. First, for both interventions, the narrow eligibility criteria of 
trials and the limited sample sizes (especially for Zolgensma) raise concerns about generalizability of 
results to the wider population of patients with SMA.  In particular, data are not available to 
evaluate the impact of treatment on patients who have been so severely affected by the SMA that 
they already require permanent ventilation and/or who have developed scoliosis that may limit the 
benefits of improved respiratory muscle function. 
 
The evidence on Spinraza, particularly in Type II-III and presymptomatic patients, is more robust 
than the early evidence on Zolgensma and provides more certainty about its intermediate-term 
effectiveness. Currently available data do not suggest diminishing benefit over time, but for both 
treatments the longer-term durability and magnitude of benefit and potential risks remain 
uncertain.  Spinraza prescribing information notes the risks of thrombocytopenia and renal toxicity, 
and clinical experts have mentioned concerns about the possible negative effects of long-term 
repeated lumbar punctures.  
 
For Zolgensma, there remains data on only a very small number of patients for a relatively short 
amount of time.  If the therapeutic gene expression wanes over time, the impact on long-term 
outcomes is uncertain.  It is also possible that antibodies to the viral vector may be generated, 
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eliminating the possibility of repeat treatment with Zolgensma.  In addition, without a randomized 
trial treatment effects judged against historical controls can exaggerate perceived treatment 
effects.  For example, in older natural history studies, approximately 68% of patients with Type I 
SMA died by two years of age.19,20 In part due to the improvements in and increased utilization of 
nutritional and respiratory support, more recent estimates of mortality are approximately 30% at 
two years of age with approximately half of survivors reliant on noninvasive ventilation.21 
 
Given the differences in baseline characteristics between the trials of Type I SMA, direct 
comparisons of relative effectiveness between Zolgensma and Spinraza should be avoided. For 
example, there are differences in age at treatment initiation and duration of disease, which are 
known to be modifiers of treatment effect. In addition, the time point of primary outcome analysis 
and approach for assessing motor milestones differ between the studies on Spinraza and 
Zolgensma.  
For presymptomatic patients, very early results suggest that treatment with Spinraza or Zolgensma 
may provide more benefit to patients than waiting until symptoms have developed. This would be 
consistent with the understanding of the pathophysiology of the condition, in which motor neurons 
are lost in an ongoing, cumulative fashion.  Whether there are greater risks for treatment of very 
young children remains highly uncertain. 
Finally, it should be noted that there are no data on concurrent or sequential use of Spinraza and 
Zolgensma.  Some patients who received Zolgensma in START went on to take Spinraza after the 
trial, but the reason these children were treated with both agents and the outcomes of this 
treatment sequence are unknown. 
 
Long-term cost-effectiveness  
We developed separate de novo economic models for Type I SMA, Type II/III) SMA, and 
presymptomatic SMA.  Spinraza was compared to best supportive care (BSC) in each model, 
whereas Zolgensma was evaluated against best supportive care solely in Type I SMA.  For each 
population, we estimated the lifetime costs, life years (LYs) gained, and quality adjusted life years 
(QALYs) gained, discounted at 3% per annum, for Spinraza and best supportive care (BSC).   
 
The models were dependent on three constructs: motor function milestones achieved, need for 
permanent ventilation, and the time to death. All three models used the same structure and 
contained two main components: a short-term model concordant with clinical study data, and a 
long-term extrapolation model.  For Zolgensma, since at the time of modeling there was no 
announced price, we used a placeholder one-time cost of $2 million for the base-case analysis.  Full 
details of each model, including all assumptions, sources for utilities and costs, and the analyses 
conducted, are available on /Z ?ƐǁĞďƐŝƚĞ. 
 
In addition to the models described above, we included in our report an analysis of a hypothetical 
 “ƌƵŐy ?ĨŽƌƉƌĞƐǇŵƉƚŽŵĂƚŝĐ^D ?ĂƐƐƵŵĞĚƚŽŚĂǀĞƚŚĞŽŶĞ-time administration and pricing 
structure of Zolgensma and the efficacy of Spinraza (used as a placeholder in the absence of data on 
Zolgensma).  We chose to present this model at the time due to our understanding that data on 
Zolgensma for presymptomatic SMA would be forthcoming, and we felt it important to provide a 
context for policymakers to consider the potential cost-effectiveness of a one-time treatment for 
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presymptomatic SMA.  As it turned out, data on Zolgensma for presymptomatic SMA were 
announced in April and May, 2019 and the FDA approval for Zolgensma included an indication for 
use in this population.  The clinical data are still preliminary and have not been subject to peer 
review, but policymakers may wish to consider the ƌĞƐƵůƚƐĨƌŽŵ/Z ?ƐŵŽĚĞůŝŶŐŽĨ “Drug X ? in 
thinking about the value of Zolgensma.  
 
Results from the health care sector perspective for the three different populations are presented 
below in Table 1. For Type I SMA model, incremental cost effectiveness ratios compared with BSC 
are approximately $1.1 million per QALY gained for Spinraza and approximately $243,000 per QALY 
for Zolgensma.  For Type II/III SMA, the incremental cost effectiveness ratio of Spinraza compared 
with BSC is approximately $8 million per QALY gained.  
 
Cost-effectiveness of SMA treatment was found to be best for patients with presymptomatic SMA.  
In the presymptomatic model, the incremental cost effectiveness ratio of Spinraza compared with 
BSC is approximately $700,000 per QALY.  &Žƌ “ƌƵŐy ? ?ƚŚĞŝŶĐƌĞŵĞŶƚĂůĐŽƐƚ-effectiveness ratio 
was $161,000 per QALY gained, and $145,000 per LYG, close to the upper bound of traditional cost-
effectiveness ranges in the US. 
 
 
Table 1: Health Care Sector Perspective Cost-Effectiveness of Spinraza, Zolgensma ?ĂŶĚ “ƌƵŐ
y ? compared to BSC for Patients with SMA 
Type I SMA: 
Spinraza 
Drug 
Treatment 
Costs 
Non-
Treatment 
Health Care 
Costs 
Total Costs QALYs LYs Incremental Results 
Cost/QALY 
Gained 
Cost/LY 
Gained 
Spinraza $2,231,000 $1,653,000 $3,884,000 3.24 7.64 $1,112,000 $590,000 
BSC $0 $789,000 $789,000 0.46 2.40 -- -- 
       
Type I SMA: 
Zolgensma 
Drug 
Treatment 
Costs 
Non-
Treatment 
Health Care 
Costs 
Total Costs QALYs LYs Incremental Results 
Cost/QALY 
Gained 
Cost/LY 
Gained 
Zolgensma $2,000,000* $1,657,000 $3,657,000 12.23 18.17 $243,000 $182,000 
BSC $0 $789,000 $789,000 0.46 2.40 -- -- 
       
Type II/III SMA: 
Spinraza 
Drug 
Treatment 
Costs 
Non-
Treatment 
Health Care 
Costs 
Total Costs QALYs LYs Incremental Results 
Cost/QALY 
Gained 
Cost/LY 
Gained 
Spinraza $7,634,000 $1,514,000 $9,148,000 12.28 18.90 $8,156,000 Dominated 
BSC $0 $1,442,000 $1,442,000 11.34 18.90 -- -- 
       
Presymptomatic 
SMA: 
Drug 
Treatment 
Costs 
Non-
Treatment 
Total Costs QALYs LYs Incremental Results 
Cost/QALY 
Gained 
Cost/LY 
Gained 
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Spinraza and 
 ?ƌƵŐy ? 
Health Care 
Costs 
Spinraza $10,565,000 $1,364,000 $11,929,000 21.94 26.58 $709,000 $652,000 
 “ƌƵŐy ? $2,000,000* $1,264,000 $3,264,000 21.94 26.58 $161,000 $145,000 
BSC $0 $801,000 $801,000 6.25 9.51 -- -- 
*Assumed placeholder price 
 
 
 
Our cost-effectiveness analyses have several limitations.  As noted earlier, there are no long-
term follow-up data available on either Spinraza or Zolgensma, resulting in considerable 
uncertainty related to the long-term outcomes of treated patients.  This uncertainty in long-
term survival was partially addressed through multiple sensitivity and scenario analyses 
presented in the full report.  Furthermore, minor gradations of improved muscle function that 
may not be captured in existing outcome measures can have real effects on patient mobility 
and quality of life.  For example, with modern technology, the ability to move just a single finger 
can enhance independence and quality of life by allowing a patient to operate an iPad or move 
the joystick of a motorized wheelchair.  In part because we were aware of this limitation in the 
recorded outcomes, we added an extra utility benefit in the treatment arms compared to BSC 
to make allowances for better functioning within broad health states. 
 
Policy Discussion 
The New England Comparative Effectiveness Public Advisory Council (New England CEPAC) is one of 
the independent appraisal committees convened by our institute to engage in the public 
deliberation of the evidence on clinical and cost-effectiveness of health care interventions.  
dŚĞEĞǁŶŐůĂŶĚWĚĞůŝďĞƌĂƚĞĚŽŶ/Z ?ƐƌĞƉŽƌƚŽŶ^ƉŝŶƌĂǌĂĂŶĚŽůŐĞŶƐŵĂĂƚĂƉƵďůŝĐ
meeting on March 7, 2019. Following discussion, the CEPAC panel members first voted unanimously 
that the evidence was adequate to demonstrate the superiority of both Spinraza and Zolgensma to 
best supportive care in Type I SMA and, for Spinraza, in Types II/III SMA as well.  Voting was 10 to 2 
that the evidence was adequate to demonstrate superiority in presymptomatic SMA for Spinraza.  
No votes were taken on Zolgensma other than for its use in Type 1 SMA.   
dŚĞWƉĂŶĞůĂůƐŽǀŽƚĞĚŽŶ “ŽƚŚĞƌƉŽƚĞŶƚŝĂůďĞŶĞĨŝƚƐ ?ĂŶĚ “ĐŽŶƚĞǆƚƵĂůĐŽŶƐŝĚĞƌĂƚŝŽŶƐ ?ĂƐƉĂƌƚŽĨ
a process intended to signal to policymakers whether there are important considerations when 
making judgments about long-term value for money not adequately captured in analyses of clinical 
and/or cost effectiveness. The results in Tables 2 and 3 highlight several factors that the CEPAC 
panel felt were particularly important for judgments of value, including the impact on caregiver 
burden and the fact that these treatments are the very first for this very severe condition.  
Zolgensma was noted by all panel members as having a reduced complexity (ie no need for ongoing 
lumbar punctures) compared to Spinraza that could improve patient outcomes in real-world 
practice. 
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Table 2. Other Benefits or Disadvantages: When compared to supportive care alone, does the 
ĂĚĚŝƚŝŽŶŽĨ^ƉŝŶƌĂǌĂŽƌŽůŐĞŶƐŵĂŽĨĨĞƌŽŶĞŽƌŵŽƌĞŽĨƚŚĞĨŽůůŽǁŝŶŐ “ŽƚŚĞƌďĞŶĞĨŝƚƐ ? ? 
Potential Benefit Panel Votes 
Spinraza Zolgensma 
This therapy offers reduced complexity compared to other 
treatment options that will improve patient outcomes in the real 
world.  
N/A 
 
12/12 
This therapy has a different mechanism of action or approach that 
will allow successful treatment of many patients for whom other 
available treatments have failed.  
N/A 
 
N/A 
This therapy will significantly reduce caregiver or broader family 
burden.  
12/12 
 
11/12 
This therapy will have a significant impact on improving 
ƉĂƚŝĞŶƚƐ ? ?ĐĂƌĞŐŝǀĞƌƐ ?ĂďŝůŝƚǇƚŽƌĞƚƵƌŶƚŽǁŽƌŬĂŶĚ ?ŽƌƚŚĞŝƌŽǀĞƌĂůů
productivity.  
10/12 
 
10/12 
This therapy will have a significant impact on the entire 
 “ŝŶĨƌĂƐƚƌƵĐƚƵƌĞ ?ŽĨĐĂƌĞ, 
including effects on screening for affected patients, on the 
sensitization of clinicians, and on the dissemination of 
understanding about the condition, that may revolutionize how 
patients are cared for in many ways that extend beyond the 
treatment itself.  
12/12 11/12 
There are other important benefits  ? or disadvantages  ? that 
should have an important role in judgments of the value of this 
therapy.  
N/A  
 
N/A 
 
 
 
Table 3. Contextual considerations: Are any of the following contextual considerations important 
in assessing the long-term value for money of Spinraza or Zolgensma? 
Contextual consideration Panel votes 
Spinraza Zolgensma 
This therapy is intended for the care of individuals with a 
condition of particularly high severity in terms of impact on 
length of life and/or quality of life.  
11/12 10/12 
This therapy is intended for the care of individuals with a 
condition that represents a particularly high lifetime burden of 
illness.  
11/12 10/12 
This therapy was the first to offer any improvement for patients 
with this condition.  
12/12 Not asked  
Compared to best supportive care, there is significant uncertainty 
about the long-term risk of serious side effects of this therapy.  
7/12 6/12 
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Compared to best supportive care, there is significant uncertainty 
about the magnitude or durability of the long-term benefits of 
this therapy.  
7/12 7/12 
There are additional contextual considerations that should have 
an important role in judgments of the value of this therapy.  
N/A 
 
N/A 
 
 
The culminating vote of the CEPAC was on the  “ůŽŶŐ-ƚĞƌŵǀĂůƵĞĨŽƌŵŽŶĞǇ ?ŽĨ^ƉŝŶƌĂǌĂĂŶĚ
Zolgensma.  Despite the strong affirmation of the clinical and broader benefits of Spinraza, the 
CEPAC voted unanimously that at current pricing it represented a low long-term value for money in 
any subset of SMA.  No vote on the value of Zolgensma was taken at this meeting given that no 
price for Zolgensma had yet been announced.  
 
The culminating policy roundtable discussion explored how best to translate the evidence and 
broader perspectives discussed into clinical practice and into pricing and insurance coverage 
policies. The full set of resulting policy recommendations can be found in the Final Evidence Report, 
and selected key perspectives on potential coverage policy considerations are described below. 
 
1.  Payers should provide responses to prior authorization requests within 48 hours.  
Diagnosis of SMA in an infant should be treated by providers and payers as an emergency requiring 
rapid decision-making and the delivery of treatment as soon as possible. Payers should develop fail-
safe mechanisms to ensure that these requests are evaluated and responded to within 48 hours. 
Payers should make every attempt to communicate with providers and families to resolve any prior 
authorization challenges as soon as possible. 
 
2.  Prior authorization criteria should reflect evolving evidence and clinical expert input. 
a. Diagnosis: Insurers should not require repeated documentation of genetic testing results.  Given 
that screening at birth will soon become universal, pre-symptomatic individuals with different 
numbers of SMN2 copies will be identified. Although genotype is not precisely predictive of 
phenotype, existing research suggests that a very small number of individuals with four or more 
copies of SMN2 will develop the most severe forms of SMA. A recent article authored by clinical 
experts from across the US, including many with research and other links to industry, found divided 
opinions on whether individuals found at birth to have four or more copies of SMN2 should be 
treated immediately or whether it was reasonable to wait and monitor them to see if any signs of 
diminished muscle function emerged. The final proposal from this group supported the option of 
surveillance with the possibility of later treatment for this subpopulation.22  
b. Age: For symptomatic patients, based on the lack of data on treatment among older patients, 
some countries have limited coverage to patients under the age of 12 or 15, but patient and clinical 
expert testimony suggests that there is no basis for assuming that benefits cannot be significant for 
patients with Type II-III at all ages.  
c. Other clinical criteria: For symptomatic patients, payers may opt to have no clinical criteria 
related to severity or they may consider the option of requiring that clinical criteria be met that 
9 
 
demonstrate that the patient is not too severely affected in some way to retain the possibility of 
benefit from treatment. For example, some payers have required that patients not be on 
permanent ventilation. Although there are no data on the benefits of initiating Spinraza treatment 
among permanently ventilated patients, family and clinical expert testimony argued that ventilated 
patients can benefit from treatment even with relatively small improvements in motor function that 
can allow the self-direction of motorized wheelchairs or the use of tablets for communication. 
 
Some countries have not provided coverage for Spinraza when patients have attained the ability to 
walk independently. Although the cost-effectiveness of treatment for symptomatic patients is 
worse among patients who are less severely affected, clinical experts and patient representatives 
argued that for some patients who can walk independently there are still important upper limb 
motor function benefits that are possible with treatment.  
 
d. Renewal criteria: Many payers will seek to set a time threshold at which coverage must be re-
assessed in light of whether there have been demonstrated benefits of treatment. Although a clear 
threshold is not evident from trial data, clinical experts advised that it is not unreasonable to expect 
results after six to 12 months of treatment. If there has been no improvement, or at least no halt to 
a steady decline in symptoms at that time, payers may determine that continued coverage for 
Spinraza is not medically necessary. Of note, some countries have used achievement or 
maintenance of sitting as a single outcome measure by which to determine whether continued use 
of Spinraza is justified, but clinical expert comment suggested that for many patients sitting is not a 
relevant measure of clinical benefit. Alternatively, given the clinical heterogeneity of patients, and 
the challenge of determining which clinical outcome measure is best suited for a specific patient, 
payers may opt for clinician attestation as the most reasonable option for determining whether 
coverage should be renewed.  
 
 
Conclusion 
 
There can be no more exciting development in medicine than the introduction of new, highly 
effective treatments for a condition that affects children and leads to substantial disability and 
death.  The evidence on Spinraza and Zolgensma is still early and, especially for Zolgensma, remains 
highly uncertain in terms of true long-term outcomes.  Nonetheless, the short-term benefits 
demonstrated in the most severe form of SMA have been substantial, and it is likely that use of 
both agents will shift toward use in presymptomatic patients as genetic screening at birth becomes 
more widespread. 
 
Despite the clinical benefits seen in early studies, economic modeling in which these early benefits 
of treatment are assumed to be durable thƌŽƵŐŚŽƵƚƉĂƚŝĞŶƚƐ ?ůŝĨĞƚŝŵĞƐĨŝŶĚƐƚŚĂƚƚŚĞŝŶĐƌĞŵĞŶƚĂů
cost-effectiveness ratio for Spinraza, at its current pricing, is far beyond the usual boundaries 
considered cost-effective for the United States health care system.  Zolgensma, however, as a one-
time therapy, gains a cost-effectiveness advantage over a treatment that must be administered in a 
ĐŚƌŽŶŝĐĨĂƐŚŝŽŶƚŚƌŽƵŐŚŽƵƚƚŚĞůŝĨĞƚŝŵĞŽĨƚŚĞƉĂƚŝĞŶƚ ?KƵƌĞĐŽŶŽŵŝĐŵŽĚĞůŝŶŐŽĨ “ƌƵŐy ?ĨŽƌ
presymptomatic SMA can serve as a surrogate for Zolgensma, and with the early data for 
ŽůŐĞŶƐŵĂŝŶƚŚŝƐƉĂƚŝĞŶƚŐƌŽƵƉŶŽǁĂƉƉĞĂƌŝŶŐ ?ǁĞďĞůŝĞǀĞƚŚĞŽůŐĞŶƐŵĂ ?ƐĂŶŶŽƵŶĐĞĚƉƌŝĐĞŽĨ
$2.1 million ůŝĞƐǁŝƚŚŝŶƚŚĞŚŝŐŚĞƐƚƉĂƌƚŽĨĂ “ĨĂŝƌ ?ĐŽƐƚ-effectiveness range.  It must be remembered 
10 
 
that the evidence on Zolgensma is early, has not yet appeared in peer-reviewed journals, and that 
its announced price would not be deemed cost-effective for treatment of the current prevalent 
SMA population.  Further research and efforts to link the price of these new treatments for SMA to 
their demonstrated long-term benefits for patients will require concerted collaborative efforts 
among manufacturers, payers, patients, and clinicians. 
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